Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial
W J Köstler, T Brodowicz, Y Attems, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 7, 2014
Pulmonary metastasectomy for soft tissue sarcoma--report from a dual institution experience at the Medical University of Vienna
S Schur, K Hoetzenecker, W Lamm, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
January 30, 1999
Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?
G J Locker, G G Steger, M F Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2013
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
T Brodowicz, T E Ciuleanu, D Radosavljevic, et al.
Breast (Edinburgh, Scotland)
|
February 18, 2004
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
T Brodowicz, W J Kostler, R Möslinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
I Lang, M J Inbar, Z Kahán, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 19, 2018
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy
N Touati, P Schöffski, S Litière, et al.
Cancer Chemotherapy and Pharmacology
|
February 28, 2001
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial
M Schmidinger, A C Budinsky, C Wenzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 27, 2012
Adjuvant therapy in primary GIST: state-of-the-art
P Reichardt, J-Y Blay, I Boukovinas, et al.
British Journal of Cancer
|
October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
T Brodowicz, I Lang, Z Kahan, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial
W J Köstler, T Brodowicz, Y Attems, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 7, 2014
Pulmonary metastasectomy for soft tissue sarcoma--report from a dual institution experience at the Medical University of Vienna
S Schur, K Hoetzenecker, W Lamm, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
January 30, 1999
Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?
G J Locker, G G Steger, M F Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2013
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
T Brodowicz, T E Ciuleanu, D Radosavljevic, et al.
Breast (Edinburgh, Scotland)
|
February 18, 2004
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
T Brodowicz, W J Kostler, R Möslinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
I Lang, M J Inbar, Z Kahán, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 19, 2018
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy
N Touati, P Schöffski, S Litière, et al.
Cancer Chemotherapy and Pharmacology
|
February 28, 2001
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial
M Schmidinger, A C Budinsky, C Wenzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 27, 2012
Adjuvant therapy in primary GIST: state-of-the-art
P Reichardt, J-Y Blay, I Boukovinas, et al.
British Journal of Cancer
|
October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
T Brodowicz, I Lang, Z Kahan, et al.
Page
of 6